About this trial
The glenohumeral joint has the highest rate of dislocation of the whole body, due to its high mobility and the special characteristics of its anatomy. It is estimated that every year between 1-2% of the population will suffer from glenohumeral dislocation. The vast majority of studies are based on young patients under the age of 40, given that at this age they have the higher incidence and at the same time, they have higher redislocation index. However, the investigators are in front of a more active population with a longer life expectancy. That is why the cases of anterior glenohumeral dislocations are increasing in people older than 40 years. Given that most studies focus on younger patients, the investigators lack knowledge about which injuries are associated with dislocation at this age and whether these influence its clinical evolution.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
More than 40 years old
First episode of traumatic anterior gelnohumeral dislocation seen in Rx
Acceptance to be checked over 2 years
Acceptance to be submitted to TAC, NMR, EMG and Bilateral Ultrasound
Disqualifiers
Previous fractures in this extremity
Previous neurovascular lesions in this extremity
Other associated lesions
Cognitive alterations or dementia which prevent completing the protocols. Patients with <14 points in Mini-mental test.
Trial population
All consecutive patients with an anterior glenohumeral dislocation and over 40 years old who came to the Emergency Room in the Hospital between June 2023 and June 2025
Trial design
Cohort
Prospective
Treatments tested in this trial
Reduction
Procedure/SurgeryAn Rx will be performed before and after the reduction of the dislocation. After that, the neurovascular state will be checked and also if there is some associated injury.
Treatment groups
Trial outcomes
Primary outcomes
Characterization of associated lesions
Secondary outcomes
Constant Functional Test
WOSI test
SST
Redislocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.